|
covid-19 |
82 |
|
sars-cov-2 |
45 |
|
covid-19 vaccine |
39 |
|
chinese |
33 |
|
children |
30 |
|
bnt162b2 |
29 |
|
coronavac |
29 |
|
vaccine safety |
29 |
|
covid-19 vaccines |
27 |
|
public health |
27 |
|
epidemiology |
22 |
|
inactivated vaccine |
18 |
|
self-controlled case series |
18 |
|
long covid |
17 |
|
child psychosocial problems |
16 |
|
coronavirus |
16 |
|
healthcare workers |
16 |
|
home confinement |
16 |
|
hospital policies |
16 |
|
perceived stress |
16 |
|
psychological wellbeing |
16 |
|
school closure |
16 |
|
vaccine effectiveness |
15 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
mortality |
14 |
|
cytokines |
13 |
|
immunoglobulin |
13 |
|
lymphocyte subsets |
13 |
|
sars |
13 |
|
chronic diseases |
12 |
|
dementia |
12 |
|
false positive |
12 |
|
health services |
12 |
|
innate immunity |
12 |
|
kawasaki disease |
12 |
|
non-communicable diseases |
12 |
|
serology |
12 |
|
tuberculosis |
12 |
|
chronic liver disease |
11 |
|
cirrhosis |
11 |
|
graves disease |
11 |
|
hepatocellular carcinoma |
11 |
|
hong kong |
11 |
|
hyperthyroidism |
11 |
|
hypothyroidism |
11 |
|
omicron |
11 |
|
paediatrics |
11 |
|
pharmacoepidemiology |
11 |
|
post-covid-19 syndrome |
11 |
|
sars-cov-2 infection |
11 |
|
statistics & research methods |
11 |
|
thyroid dysfunction |
11 |
|
adverse events |
10 |
|
all-cause pneumonia |
10 |
|
atrial fibrillation |
10 |
|
autoimmune disorders |
10 |
|
delirium |
10 |
|
herd immunity |
10 |
|
incident cvd |
10 |
|
interrupted time series analysis |
10 |
|
ischemic stroke |
10 |
|
major adverse cardiovascular events |
10 |
|
pasc |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
sex difference |
10 |
|
adverse events of special interest (aesi) |
9 |
|
age-stratified |
9 |
|
asia |
9 |
|
cancer |
9 |
|
cardiovascular complications |
9 |
|
diabetes |
9 |
|
heart failure |
9 |
|
infection |
9 |
|
microvascular complications |
9 |
|
molnupiravir |
9 |
|
myocardial infarction |
9 |
|
nirmatrelvir-ritonavir |
9 |
|
pediatrics |
9 |
|
pharmacovigilance |
9 |
|
safety |
9 |
|
stroke |
9 |
|
travel history |
9 |
|
vaccine |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
abdominal pain |
8 |
|
adverse events of special interest |
8 |
|
antivirals |
8 |
|
biological sciences |
8 |
|
cardiovascular diseases |
8 |
|
ckd |
8 |
|
diarrhoea |
8 |
|
drug regulatory |
8 |
|
ehr |
8 |
|
emulated trial |
8 |
|
health equity |
8 |
|
health sciences |
8 |
|
machine learning |
8 |
|
mrna vaccine |
8 |
|
myocarditis |
8 |
|
orphan drug policy |
8 |
|
paediatric gastroenterology |
8 |
|
pediatric population |
8 |
|
pericarditis |
8 |
|
rare diseases |
8 |
|
recurrent cardiovascular events |
8 |
|
risk prediction score |
8 |
|
treatment access |
8 |
|
blood pressure |
7 |
|
carbapenemase-producing enterobacteriaceae |
7 |
|
cardiovascular disease |
7 |
|
carriage |
7 |
|
cervical screening |
7 |
|
diabetes mellitus |
7 |
|
general practice |
7 |
|
geriatrics |
7 |
|
hospitalisation |
7 |
|
hpv vaccination |
7 |
|
mental disorders |
7 |
|
nested case-control study |
7 |
|
primary health care |
7 |
|
risk factor |
7 |
|
sexual behaviour |
7 |
|
vaccination |
7 |
|
visit‐to‐visit variability |
7 |
|
adverse drug reactions |
6 |
|
antimicrobial stewardship |
6 |
|
data repository |
6 |
|
effectiveness |
6 |
|
meta-data |
6 |
|
neurogen |
6 |
|
neurological and mental health global epidemiology network |
6 |
|
prescribing |
6 |
|
real-world evidence |
6 |
|
respiratory tract infections |
6 |
|
type 2 diabetes |
6 |
|
cardiovascular disease risk |
5 |
|
low-density lipoprotein cholesterol |
5 |
|
percutaneous coronary intervention |
5 |
|
secondary prevention |
5 |
|
statins |
5 |
|
transient ischaemic attack |
5 |
|
treatment outcome |
5 |
|
type 2 diabetes mellitus |
5 |
|
young age of onset |
5 |
|
adhd |
4 |
|
antimicrobials |
4 |
|
atomoxetine |
4 |
|
attention deficit hyperactivity disorder |
4 |
|
database |
4 |
|
meta-analysis |
4 |
|
methylphenidate |
4 |
|
prevalence |
4 |
|
retinal detachment |
4 |
|
rheumatoid arthritis |
4 |
|
sudden death |
4 |
|
taiwan |
4 |
|
tofacitinib |
4 |
|
toxic epidermal necrolysis (ten) |
4 |
|
antipsychotic |
3 |
|
china |
3 |
|
elderly |
3 |
|
lorcaserin |
3 |
|
meta‐analysis |
3 |
|
methodology |
3 |
|
micronutrients |
3 |
|
observational study |
3 |
|
pharmacy and pharmacology |
3 |
|
pregnancy |
3 |
|
prescribing trend |
3 |
|
retina |
3 |
|
weight loss |
3 |
|
accident and emergency |
2 |
|
adolescent |
2 |
|
attention deficit disorder with hyperactivity |
2 |
|
child |
2 |
|
comorbidity |
2 |
|
electronic health records |
2 |
|
epilepsy |
2 |
|
fluoroquinolones |
2 |
|
healthcare utilization |
2 |
|
hospitalizations |
2 |
|
humans |
2 |
|
retina - diseases |
2 |
